Orphan Therapeutics, LLC is aprivately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for its first product, Lucassin® (terlipressin), for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US, Canada, Japan and Australia.
